Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2023-06-25
DOI
10.1093/jnci/djad120
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer
- (2022) Adele M. Nicolas et al. CANCER CELL
- Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
- (2022) Walid K. Chatila et al. NATURE MEDICINE
- Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
- (2021) Thierry Conroy et al. LANCET ONCOLOGY
- Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis
- (2021) Sanne ten Hoorn et al. JNCI-Journal of the National Cancer Institute
- Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
- (2021) Emmanouil Fokas et al. JAMA Oncology
- Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
- (2020) T. André et al. ANNALS OF ONCOLOGY
- Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
- (2020) Renu R Bahadoer et al. LANCET ONCOLOGY
- Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma
- (2019) Carlos Fernández-Martos et al. JAMA Oncology
- Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
- (2016) Etienne Becht et al. CLINICAL CANCER RESEARCH
- Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
- (2016) Anne Trinh et al. CLINICAL CANCER RESEARCH
- Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
- (2016) Rachel S Kerr et al. LANCET ONCOLOGY
- Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion
- (2016) T T Vellinga et al. ONCOGENE
- Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes
- (2016) Nan Song et al. JAMA Oncology
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
- (2012) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study
- (2010) Carlos Fernández-Martos et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now